Correction to: A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler^® to Budesonide/Formoterol Easyhaler^®

Jörgen Syk^{1

2

3}, Ines Vinge⁴, Mikael Sörberg⁵, Mikko Vahteristo⁶, Paula Rytilä⁷

Affiliations

¹ Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
² Academic Primary Health Care Centre, Stockholm, Sweden.
³ Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
⁴ Asthma-Allergy-Lung Department, Lidingö Hospital, Lidingö, Sweden.
⁵ Orion Pharma, Danderyd, Sweden.
⁶ Orion Corporation, Orion Pharma, Kuopio, Finland.
⁷ Orion Corporation, Orion Pharma, Espoo, Finland. paula.rytila@orionpharma.com.

Published Erratum

Jörgen Syk et al. Adv Ther. 2019 Jul.

. 2019 Jul;36(7):1770.

doi: 10.1007/s12325-019-00975-w. Epub 2019 Jun 9.

Jörgen Syk^{1

2

3}, Ines Vinge⁴, Mikael Sörberg⁵, Mikko Vahteristo⁶, Paula Rytilä⁷

¹ Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
² Academic Primary Health Care Centre, Stockholm, Sweden.
³ Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
⁴ Asthma-Allergy-Lung Department, Lidingö Hospital, Lidingö, Sweden.
⁵ Orion Pharma, Danderyd, Sweden.
⁶ Orion Corporation, Orion Pharma, Kuopio, Finland.
⁷ Orion Corporation, Orion Pharma, Espoo, Finland. paula.rytila@orionpharma.com.

Abstract

Unfortunately, the mean difference in change from baseline ACT was incorrectly reported in the abstract as 19.0 vs. 20.8 instead of 18.9 vs. 20.7.

A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler^® to Budesonide/Formoterol Easyhaler^®.
Syk J, Vinge I, Sörberg M, Vahteristo M, Rytilä P. Syk J, et al. Adv Ther. 2019 Jul;36(7):1756-1769. doi: 10.1007/s12325-019-00940-7. Epub 2019 Apr 2. Adv Ther. 2019. PMID: 30941722 Free PMC article.